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ABSTRACT 
Aim To investigate the epidemiology, clinical profile and risk factors of pseudotumor cerebri syndrome 
(PTCS) in children aged 1-16 years.  
Methods A national prospective population-based cohort study over 25 months. Newly diagnosed 
PTCS cases notified via British Paediatric Surveillance Unit (BPSU) were ascertained using classical 
diagnostic criteria and categorised according to 2013 revised diagnostic criteria. We derived national 
age, sex and weight-specific annual incidence rates and assessed effects of sex and weight category.  
Results We identified 185 PTCS cases of which 166 also fulfilled revised diagnostic criteria. The 
national annual incidence (95% CI) of childhood PTCS aged 1-16 years was 0.71 (0.57- 0.87) per 
100,000 population increasing with age and weight to 4.18 and 10.7 per 100,000 in obese 12-15 year 
old boys and girls respectively. Incidence rates under 7 years were similar in both sexes. From 7 years 
onwards, the incidence in girls was double that in boys, but only in overweight (including obese) 
children. In 12-15 year old children, an estimated 82% of the incidence of PTCS was attributable to 
obesity. Two subgroups of PTCS were apparent: 168 (91%) cases aged from 7 years frequently 
presented on medication and with headache, and were predominantly female and obese. The remaining 
17 (9%) cases under 7 years often lacked these risk factors and commonly presented with new onset 
squint.   
Conclusions This uniquely largest population-based study of childhood PTCS will inform the design 
of future intervention studies.  It suggests that weight reduction is central to the prevention of PTCS.  
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INTRODUCTION 
Pseudotumor cerebri syndrome (PTCS), also known as idiopathic intracranial hypertension, is a rare 
syndrome of raised intracranial pressure (ICP) first described in 1893.1 Its annual incidence in adults 
and children has been estimated to be 1.6-2.22-4 and 0.5-0.95-7 per 100,000 respectively although the 
latter estimates are based on small or retrospective studies. PTCS has potentially serious morbidities of 
distressing headache, blindness,8 9 and complications of invasive treatment procedures. Its management 
remains controversial.    
 
Classical diagnostic criteria for PTCS, in use since 1937,10 combine the absence of other causes of 
raised ICP, including mass lesions and cerebral venous sinus thrombosis (CVST), with the presence of 
three cardinal features: symptoms of raised ICP, papilloedema and elevated opening cerebrospinal fluid 
(CSF) pressure at lumbar puncture (LP).11  These criteria provided the present study case definition 
(Table 1A). Although CVST excludes the diagnosis of PTCS, the presence of risk factors does not and 
it is therefore not ‘idiopathic’. The fidelity of the clinical diagnosis of PTCS may be reduced first by 
misdiagnosis of papilloedema when evaluated by clinicians lacking access to specialist 
ophthalmological assessment12 and second by estimation of CSF pressure based on brief recording of 
lumbar CSF opening pressure. This varies with posture, movement, emotion, anaesthetics and 
hypercapnia, and may not accurately reflect mean CSF pressure.13  
 
An increase in the upper normal threshold of lumbar CSF opening pressure from 20 cm to 25 cm CSF 
in non-obese children and 28 cm in children who are either obese or sedated for their LP has been 
proposed.14 Furthermore, specific (but insensitive) neuroradiological markers of raised ICP have been 
established.15-19 In 2013, Friedman et al. published revised diagnostic criteria for PTCS that 
incorporated these changes but did not include symptoms of raised ICP (Table 1B).20 The revised 
criteria categorise PTCS as ‘definite’ (elevated CSF pressure and either papilloedema or abducens 
nerve palsy), ‘probable’ (papilloedema but normal CSF pressure) or ‘suggestive of PTCS’ (lacking 
papilloedema and abducens nerve palsy but manifesting elevated CSF pressure plus at least three valid 
neuroimaging markers of raised ICP).20   
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This study aimed to establish the incidence of childhood PTCS reliably, quantify the impact of known 
risk factors and identify clinical subgroups.   
 
METHODS 
We ascertained newly diagnosed PTCS cases aged 1-16 years presenting over a 25-month period 
(August 2007-October 2009) to general or specialised paediatricians in the UK or Ireland using the 
monthly reporting scheme of the British Paediatric Surveillance Unit (BPSU).21 Notifying clinicians 
completed questionnaires detailing demographics, referral source, presentation, prior medications and 
medical conditions, and anthropometric, ophthalmological, CSF and neuroimaging data. YYM assessed 
jointly with at least one co-author whether the submitted data fulfilled the study case definition (Table 
1A). The validity of the diagnosis was checked with the notifying clinician one year after diagnosis. 
Data collection concluded in July 2013. Each valid PTCS case was then categorised according to the 
subsequently published revised diagnostic criteria (Table 1B).  
 
CSF opening pressure reported above a recorded value was rounded up to the nearest integer (e.g. 
‘>40cm’ became ‘41cm’). The age- and sex-specific annual incidence for eligible PTCS cases was 
determined from contemporary population estimates22 23 and evaluated in three age categories: 1-6, 7-11 
and 12-16 years. The choice of these three age categories was based on previous reports of variation of 
incidence rates with age and puberty status. Age-specific incidences for each year of age within each 
age band did not differ significantly from each other (data not shown). 
 
Participants’ growth data were expressed as z-scores of body mass index (or weight, when height was 
unavailable) in three weight categories: non-overweight (z-score <1.04 = <85th percentile), overweight 
(excluding obese) (z-score ≥1.04 to <1.64 = ≥85th to <95th percentile) and obese (z-score ≥1.64 = ≥95th 
percentile) relative to the sex and age specific 1996 British Growth reference population.24  The weight-
specific annual incidence of PTCS for  cases aged 4-6, 7-11 and 12-15 years was derived relative to the 
prevalence of these weight categories in national health surveys that were available for those age 
ranges.25 The UK and Republic of Ireland population age 1-16 years during the survey was 12,451,742 
of which 6,375,886 were male. The population aged 4-15 years included 1,604,499 males among 
5 
 
3,003,247 overweight children. Age-, sex- and weight-specific annual incidence rates were calculated 
with 95% Confidence Intervals (CI) based on the Poisson distribution. 
 
Continuous data were summarised as median values with interquartile ranges (IQRs) and categorical 
data as n (%). Homogeneity of variance was assessed with the Levene F test. Case-wise deletion was 
performed for missing data. Groups were compared by Mann-Whitney U or Kruskal-Wallis tests and 
Fisher’s Exact test for continuous and categorical data respectively. The impact of the known risk 
factors for PTCS was expressed as Relative Risk (RR), Population Attributable Risk (PAR) and 
Percentage PAR (%PAR). IBM SPSS Statistics 21 was used with two-tailed statistical testing at 
p<0·05.   
 
This study was approved by the East London & The City Research Ethics Committee, the Patient 
Information Advisory Group and the North Wales NHS Research & Development. 
 
RESULTS 
Of 379 notifications, 185 (49%) fulfilled the study case definition for newly diagnosed PTCS (Figure 
1). Of these, 124/185 (67%) were girls, 167/185 (90%) were of white ethnicity and 157/185 (85%) 
were directly referred to general paediatricians. The mean case accrual rate and percentage of cases 
relative to total notifications for each 6-month period remained steady throughout the 25-month survey 
at 46 (range 44-48) cases and 50% (range 42-57) respectively. The diagnosis remained valid in all 
163/185 (88%) eligible cases for whom one year follow-up data were available (Figure 1).  
 
Incidence by age, sex and weight category 
The annual incidence of PTCS (95% CI) aged 1-16 years was 0.71 (0.57-0.87) per 100,000 population. 
The age-specific incidence increased from 0.17, to 0.75 and then to 1.32 per 100,000 in 1-6, 7-11 and 
12-16 year olds respectively (Appendix Figure e1). Incidence rates in girls vs boys were 0.19 vs 0.16, 
1.06 vs 0.46 and 1.85 vs 0.82 per 100,000 in these respective age categories (Appendix Figure e1). 
Annual incidence per 100,000 obese population increased with age in 4-6, 7-11 and 12-15 year olds 
from 0.45 to 1.24 and then to 4.18 in boys and from 0.56 to 3.44 and then to 10.7 in girls (Appendix 
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Figure e1). The incidence remained low at 0.18 to 0.42 per 100,000 among non-overweight boys and 
girls throughout the 4-15 year age range (Appendix Figure e1). 
  
Weight and height measurements were available in 100% and 94% of cases respectively. Twenty-one 
(11%) cases were overweight and 120/185 (65%) were obese (Figure 2). In both sexes, the percentage 
of obese cases increased significantly with age (p<0.01) across the age categories from 41% (7/17), to 
50% (29/58) and then to 76% (84/110) (p<0.001). The relative risks (RR) of PTCS associated with 
obesity relative to non-overweight children of the same age and sex were 3.6 and 8.1 in 7-11 year old 
boys and girls respectively and 23.3 and 26.2 in 12-15 year old boys and girls respectively (Figure 3). 
Among overweight (including obese) children, the RR for PTCS in girls relative to boys was 3.7 in 7-
11 year olds and 2.4 in 12-15 year olds (Figure 3).  
 
Key diagnostic and neurological features  
The triad of raised ICP symptoms, papilloedema and elevated CSF pressure, was seen in 83% 
(153/185) and 73% (136/185) of those using the study and higher revised14 CSF pressure threshold 
criteria respectively (Figure 1). Papilloedema, symptoms of raised ICP and elevated CSF pressure were 
absent in 11% (20/185), 4% (8/185) and 2% (4/185) respectively or, using the revised CSF pressure 
threshold14 9% (16/185), 4% (7/185) and 11% (21/185) of cases (Figure 1). There were no differences 
between cases with and without any one of the three diagnostic cardinal features with respect to other 
presenting features, sex, age and weight categories, or other risk factors. 
 
Headache was present in 161/185 (87%) cases. Diplopia, blurring of vision or transient visual loss were 
reported in 87/161 (54%) with and 15/24 (62%) cases without headache. One or more other 
neurological features were reported in 70/185 (38%) cases (32 abducens nerve palsy, 19 new  
presentation of squint, 17 dizziness, 12 photophobia, 8 neck stiffness/pain, 5 ataxia/falling, 4 tinnitus, 3 
vertigo, 2 each of facial weakness, torticollis, nystagmus, vertigo, paraesthesia and pain behind eyes).  
 
Papilloedema was reported in 165/185 (89%), was unilateral in 13/185 (7%) and was detected 
incidentally in 5/185 (3%) asymptomatic cases. Ophthalmologists confirmed its presence in all but five 
cases and also affirmed its absence in the 20/185 (11%) cases without papilloedema. Optic nerve head 
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drusen (ONHD) was co-existent with papilloedema in 8/185 (4%), absent in 134/185 (72%), and 
uncertain in 27/185 (15%) cases. Of 32/185 (17%) cases with abducens nerve palsy, 30/32 (94%) were 
accompanied by papilloedema.  
 
New presentation of decreased visual acuity (DVA) and/or restricted visual fields (RVF) at diagnosis 
were reported in 61/185 (33%) of the 182/185 (98%) cases whose vision was assessed. Seventeen had 
DVA, 32 RVF, 11 both DVA and RVF and 1 unspecified visual defects. Of those with a visual deficit, 
54/61 (89%) had papilloedema. No differences were detected in the proportion of visual deficit 
between sexes, age or weight categories.  
 
Comparison of cases fulfilling study and revised diagnostic criteria  
Of the 185 valid study cases, PTCS diagnosis was classified on revised criteria as ‘definite’ in 144 
(78%), ‘probable’ in 22 (12%), not present in 4 (2%) cases and ‘undetermined’ in 15 (8%)  in whom 
the presence (or not) of neuroimaging criteria required for the ‘suggestive of PTCS’ category had not 
been assessed (Figure 1).  The 166 ‘definite’ or ‘probable’ PTCS cases did not differ from the other 19 
cases with respect to age, sex, weight category, other associations or clinical features other than 
papilloedema.  
 
Relation of neurological features to age and weight 
The report of headache increased from 41% (7/17) of 1-6 year olds to 91% (53/58) of 7-11 year olds 
and stabilised at 90% (99/110) of 12-15 year olds (p<0.001, Figure 4). The incidence of blurring of 
vision also increased across these age categories from 24% (4/17) to 28% (16/58) then to 53% (58/110) 
(p=0.002, Figure 4). Conversely, there was a reduction in new onset squint with successive age 
categories from 29% (5/17) to 9% (5/58) then to 8% (9/110) respectively (p=0.024) and of transient 
visual loss from 35% (6/17) to 10% (6/58) then to 9% (10/110) respectively (p=0.007) (Figure 4).  
 
Risk factors for PTCS and their relation to age and sex 
Ninety-three (50%) cases had one and 61 (33%) had more than one recognised risk factor at diagnosis 
(Appendix Table e1). Overweight or obesity was the only risk factor in 87/185 (47%) and was 
accompanied by other risk factors in 54/185 (29%) cases (Appendix Table e1). Among 46/185 (25%) 
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cases on medication, 16 (9%) had a medical condition and girls were overrepresented (40/124 or 32% 
vs 6/61 or 10%, p=0.001). A further 21(11%) cases had a medical condition without associated 
medication. The commonest reported medical conditions were migraine, in 18/185 (10%), and 
antibiotic use for acne, in 10/185 (5%). The percentage of cases with risk factors increased with 
successive age categories from 59% (10/17) to 76% (44/58) then to 91% (100/110) (p=0.001). 
 
Neuroimaging and CSF findings 
All cases had cranial neuroimaging and this included venography in 111/185 (60%). Those with and 
without venography did not differ with respect to age, sex, weight, clinical features or other risk 
factors. At least one neuroimaging criteria of raised ICP20 (Table 1B) was reported in 10/185 (5%) 
cases, all of whom had papilloedema but four lacked elevated CSF pressure on revised criteria.  
 
The median CSF opening pressure was 35.5cm CSF (range 12.0-74.0). It did not differ significantly 
between sexes or age categories, cases with and without headache or with and without papilloedema 
but was significantly higher in obese than other weight categories cases (p=0.004) and in the 82 cases 
whose LPs were undertaken with general anaesthesia (GA) compared to the 100 cases undertaken  
without GA ( p=0.001) (Appendix Figure e2). However, the percentage of cases whose LP required GA 
did not differ between weight categories.  
 
DISCUSSION 
This is the largest study of childhood PTCS to date and shows that the incidence increases eightfold 
from that in 1-6 years to that in 12-16 years and the numbers of girls and boys changes from being 
equal under the age of seven to two girls for each boy thereafter. These shifts were linked to obesity 
accounted for over four-fifths of the increased incidence among those aged 12-15 years. Even with the 
upwardly revised CSF pressure threshold,14 nearly three-quarter of cases had a classic triad of raised 
ICP symptoms, papilloedema and elevated CSF pressure and the clinical profile did not differ in other 
ways between cases with and without any one of the three cardinal features.   
  
On revised diagnostic criteria20 90% of cases captured by the study definition were classified as 
‘definite’ or ‘probable’ PTCS and did not differ clinically from the remaining 10% except in 
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manifesting papilloedema. This is consistent with PTCS being a single entity that includes either 
papilloedema or elevated CSF pressure or both. While PTCS is thus distinct, the findings on magnetic 
resonance venography and CSF haemodynamics are similar to those in the ‘slit ventricle syndrome’ of 
elevated CSF pressure.26 Slit ventricle syndrome is defined in patients with symptoms of raised ICP due 
to intraventricular shunt malfunction with slit-like radiological appearance of small ventricles. This 
usually arises when intermittent and functional shunt obstruction is associated with decreased 
compliance of the tissues surrounding the cerebral ventricles.  
 
Although 90% were of white ethnicity, PTCS were reported in all ethnic groups. We believe this truly 
represents our nationwide paediatric practice. A smaller series of cases in California found similar 
relationships to those seen in the present study between age, sex and overweight, but also observed a 
significant increase in the risk of PTCS in non-Hispanic white children relative to that in Hispanic 
white or Asian/Pacific Island chldren.27  
 
Cases under 7 years were less likely to have identifiable risk factors or to complain of headache or 
blurred vision but more likely to report transient visual loss and manifest squint. Their immature 
language skills may account for the differences in expressing symptomatology subjectively. However, 
their commoner squint presentation and the lack of association with sex, overweight or medication use  
may reflect late presentation and/or a different  pathophysiology. Dysregulation of glucocorticoid 
signalling can alter ICP dynamics and cause elevation of ICP in obese individuals28 whereas the 
mechanisms of PTCS in non-overweight younger children remain unclear.  
 
A strength of this study is that it is potentially free from intentional or unintentional bias:  the robust 
BPSU scheme for reporting cases prospectively has  94% reporting rate29 by unselected general and 
specialised paediatricians across the UK and Ireland whose rate of reporting and case detection was 
consistent  throughout the survey period. It is very improbable that any confirmed childhood PTCS 
cases were managed without the involvement of a paediatrician and the study case definition was 
inclusive so this study is likely to have captured the full spectrum of newly diagnosed PTCS.  
Nevertheless, missed or unreported cases are inevitable with the voluntary BPSU reporting scheme and 
our estimates should be regarded as an estimate of the minimum incidence rate. We cannot exclude the 
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possibility that a higher proportion of all overweight cases were ascertained due to paediatricians 
having a higher index of suspicion of the disorder in those children. We did not have an alternative 
source of information from which to estimate incidence or confirm completeness of ascertainment 
using capture/recapture analysis.   
 
Other strengths of the study were the avoidance of diagnostic error by evaluation of suspected 
papilloedema and drusen  (ONHD) by ophthalmologists, submission of weight and height data, 
documentation of GA use at LP, confirmation of the diagnosis one year later, neuroimaging including 
exclusion of CVST which may be clinically indistinguishable from PTCS.30 31  Limitations of the study 
include  the lack of standardisation in the method of assessment of opening CSF pressure and the 
failure of neuroradiological reports, in most cases, to give specific consideration to potential specific 
neuroradiological markers of raised ICP thus reducing the number of cases that could be categorised as 
‘suggestive of PTCS’.  
  
Over-diagnosis of PTCS relative to the study case definition was present in 13% of notifications. This 
carries a potential risk of harm suggesting the need for greater awareness of the diagnostic criteria 
among paediatricians. The higher CSF opening pressures seen in children that were obese or had GA 
for LP support the upwards revision of the diagnostic CSF pressure threshold in these children.  
 
In summary, this study provides three important findings relating to childhood PTCS. First, it suggests 
that it is a unitary syndrome and describes its epidemiology reliably. These observations should be 
generalisable to populations of similar ethnicity and weight profile. Second, it established female sex 
and obesity as the dominant risk factors from age 7 years. Third, it shows that children aged under 7 
years do not show these risk factors and may present somewhat differently. The age, sex and weight-
specific PTCS incidence data will help investigators to estimate the size of the population required to 
achieve an adequately powered interventional trial.  These data also suggest that the avoidance of 
overweight and weight reduction may have considerable potential impact as primary and secondary 
preventive measure for PTCS in children over the age of 7 years. . 
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What is already known on this topic?        
 Pseudotumor cerebri syndrome (PTCS) is a rare syndrome of intracranial hypertension defined by 
an evolving diagnostic algorithm, most recently revised in 2013.  
 Risk factors for PTCS including female sex and obesity.  
 The epidemiology of PTCS in childhood has not been reliably established in a prospective study 
but is thought to be lower than that in adults.  
 
What this study adds? 
 This prospective survey of all cases in Great Britain and Ireland is the largest study of PTCS in 
childhood and establishes, for the first time, reliable estimates of age, sex and weight specific 
annual incidence rates.  
 In a few, childhood PTCS occurs prior age of 7 years, often without identifiable risk factors and 
with some distinctive features in its clinical presentation.  
 Most childhood PTCS occurs from age 7 years when it is twice as common in girls and 
progressively commoner with increasing age and degrees of overweight. More than 80% of PTCS 
in 12-15 year olds is attributable to obesity.   
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Table 1 Diagnostic criteria for pseudotumor cerebri syndrome in children 
A: Classical criteria (study case definition) B: Proposed revised diagnostic criteria (adapted from Friedman et al 201320) 
All 3 essential criteria All 3 essential criteria 
1. Normal conscious level 
2. No structural cause for clinical features of 
raised ICP such as ventricular dilatation, 
cerebral or vascular lesion or CVST on 
cranial neuroimaging and/or MR/CT 
venography  
3. Normal CSF microscopy and 
biochemistry 
1. Normal neurological examination except for specified cranial nerve palsies 
2. MR or contrast-enhanced CT neuroimaging: 
a. For typical obese female patients: normal brain parenchyma and no evidence 
of hydrocephalus, mass, structural lesion or abnormal meningeal enhancement  
b. For atypical non-obese, prepubertal or patients at high risk for CVST: 
neuroimaging as for typical obese female patients but also exclusion of CVST 
by venography  
3. Normal CSF microscopy and biochemistry 
AND AND 
at least 2 of the following 3 key features: 
 
1. Symptoms of raised ICP: headache, 
nausea, vomiting or irritability and/or 
specific visual symptoms of diplopia, 
blurring of vision or transient visual loss 
 
2. Papilloedema (bilateral or unilateral) 
 
3. Elevated LP opening CSF pressure*  
 
 
 
for ‘Definite’ diagnosis 
Either presence of both papilloedema and elevated CSF opening pressure**   
Or if no papilloedema, presence of abducens nerve palsy and elevated CSF opening 
pressure**  
 
for ‘Probable’ diagnosis 
Presence of papilloedema but no elevated CSF opening pressure** 
 
for ‘Suggestive’ of diagnosis 
If absence of both papilloedema and abducens nerve palsy but presence of elevated CSF 
opening pressure** and at least 3 out of 4 neuroimaging criteria i.e. empty sella, 
flattening of the posterior aspect of the globe, transverse venous sinus stenosis and 
distension of the peri-optic subarachnoid space with or without a tortuous optic nerve 
ICP, intracranial pressure; CVST, cerebral venous sinus thrombosis; MR, Magnetic Resonance; CT, Computed Tomography; LP, lumbar 
puncture; CSF, cerebrospinal fluid.  
* >20cm CSF based on published consensus for children i.e. the lower value of the upper normal limits in adults11 
** ≥25cm CSF in non-obese and unsedated child or ≥28cm CSF if obese and/or sedated for LP14 
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Figure 1 
 
 
 
 
  
Total notifications of newly diagnosed PTCS cases 379  Details of 102 excluded notifications: 
Excluded notifications (full details on the right) 102 (27%)  36 Not meeting study case definition 4 CVST 
No questionnaires returned (included 3 duplicates)   46 (12%)  29 Historic cases 4 Optic nerve head drusen 
Duplicates of eligible PTCS cases    46 (12%)  15 Reporting error 1 Optic neuritis 
Eligible PTCS cases that fulfilled study case 
definition (Table 1A)  185 (49%) 
 13 Duplicates: 7 not meeting study case definition, 3 historic cases  
                         and 3 reporting error  
    
                            
185 cases fulfilling study case definition of PTCS (Table 1A)  
185 cases fulfilling study case definition of PTCS (Table 1A) 
Categorisation by cardinal features of PTCS 
CSF pressure relative to 
threshold level 
 
study 
threshold a         
N (%) 
revised 
threshold b 
N (%) 
 
Categorisation by revised diagnostic criteria 
(Table 1B) N (%) 
Papilloedema, symptoms of raised ICP & elevation  
of CSF pressure 153 (83%) 136 (73%) 
 Definite PTCS: papilloedema or abducens nerve 
palsy* & elevation of CSF pressure    144 (78%) 
Symptoms of raised ICP & elevation of CSF 
pressure, no papilloedema  20 (11%) 16 (9%) 
 Probable PTCS: papilloedema, no elevation of CSF 
pressure  22 (12%) 
Papilloedema & elevation of CSF pressure, no 
symptoms of raised ICP  8 (4%)  7 (4%) 
   Suggestive of PTCS: elevation of CSF pressure, no 
papilloedema nor abducens nerve palsy. This 
category was undetermined as neuroimaging data 
incomplete 
15 (8%) Papilloedema & symptoms of raised ICP, no 
elevation of CSF pressure  4 (2%)  21 (11%) 
 
Papilloedema, no symptoms of raised ICP nor 
elevation of CSF pressure          0  5 (3%) 
 Not PTCS on revised criteria  4 (2%) 
     
Follow-up data at 1 year post-diagnosis of PTCS    
Confirmed PTCS diagnosis remained valid 163 (88%)    
Reported lost to follow-up      8 (4%)    
No information available    14 (8%)    
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Figure 3  
  
 
PAR1 %PAR1 
1.88* 
0.87* 
0.55* 
0.20* 
        0.06 
        0.04 
 
82% 
83% 
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       18% 
       15% 
 
 
 
 
 
  
 
PAR %PAR 
          0.11 
    1.65* 
          0.04 
    0.83* 
    0.001 
          0.08 
       39% 
40% 
       10% 
 56% 
  0.3% 
        25% 
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FIGURE LEGENDS 
 
Figure 1 
Notifications and cases fulfilling diagnostic criteria for pseudotumor cerebri syndrome 
 
CVST Cerebral Venous Sinus Thrombosis 
a: >20cm of CSF.11  
b:  ≥25cm CSF in non-obese and unsedated child; ≥28cm CSF if obese and/or sedated for LP. 14 
* One definite PTCS case without papilloedema had abducens nerve palsy & elevated CSF pressure 
 
Figure 2 
Number of cases of pseudotumor cerebri syndrome by age, sex and weight category 
Non overweight:  BMI or weight Z-score <1.04 = <85th percentile 
Overweight:  BMI or weight Z-score ≥1.04 to <1.64 = ≥85th to <95th percentile 
Obese:   BMI or weight Z-score ≥1.64 = ≥95th percentile 
 
Figure 3 
Risk of pseudotumor cerebri syndrome associated with obesity and female sex by age 
RR, Relative Risk; error bar, 95% confidence interval (CI); PAR, Population Attributable Risk.  
* the observed RR is statistically significant i.e. 95% CI does not include unity. 
 
Upper panel: Association between obesity and incidence of pseudotumor cerebri syndrome by sex and age category.  
RR of PTCS in obese versus non-overweight children is the ratio of the annual PTCS incidences in obese and non-overweight 
children, adjusted for age category and sex.  
PAR of obesity = annual PTCS incidences in obese and non-overweight children – annual PTCS incidence in non-overweight 
children 
%PAR of obesity = (PAR of obesity x 100)/annual PTCS incidence in obese and non-overweight children.  
 
Lower panel: Association between female sex and incidence of pseudotumor cerebri syndrome by age and weight categories 
RR in girls versus boys is the ratio of annual PTCS incidence rates in girls and boys, adjusted for age and weight categories.  
PAR of female sex = annual PTCS incidence in all child population – annual PTCS incidence in boys 
%PAR of female sex = (PAR of female sex x 100)/annual PTCS incidence of the total child population 
 
 
Figure 4 
Number and percentage of neurological features and risk factors of childhood pseudotumor cerebri by age category 
* p<0.05 
 
 
